Justin Klee sold $3.0M of Amylyx Pharmaceuticals stock
By AlphaYouPublished Form 4
Klee Justin B.
Reporting filer
Justin Klee reported selling 100,000 shares of Amylyx Pharmaceuticals, Inc. for about $3.0M ($29.84 a share on average). Form 4 filed Nov 12, 2026 lists 2 entries.
See the price move since this trade →
- Disclosed
- Nov 12, 2026
Reported details
2 entries| Security | Owner | Date | Code | Action | Quantity | Price | Following holdings | Reporting delay | Filed terms and references |
|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Klee Justin B. | 2026-11-09 | S | Sale | 37483 | 29.3917 | 3,575,573 | 3 days | Filed terms
|
| Common Stock | Klee Justin B. | 2026-11-09 | S | Sale | 62517 | 30.1062 | 3,513,056 | 3 days | Filed terms
|
Common Stock
- Owner
- Klee Justin B.
- Date
- 2026-11-09
- Code
- S
- Action
- Sale
- Quantity
- 37483
- Price
- 29.3917
- Following holdings
- 3,575,573
- Reporting delay
- 3 days
- Filed terms and references
Filed terms
- security Title: Common Stock
- transaction Date: 2026-11-09
- transaction Form Type: 4
- transaction Code: S
- equity Swap Involved: false
- id: F1
- transaction Shares: 37483
- transaction Price Per Share: 29.3917
- id: F2
- transaction Acquired Disposed Code: D
- shares Owned Following Transaction: 3575573
- direct Or Indirect Ownership: D
Common Stock
- Owner
- Klee Justin B.
- Date
- 2026-11-09
- Code
- S
- Action
- Sale
- Quantity
- 62517
- Price
- 30.1062
- Following holdings
- 3,513,056
- Reporting delay
- 3 days
- Filed terms and references
Filed terms
- security Title: Common Stock
- transaction Date: 2026-11-09
- transaction Form Type: 4
- transaction Code: S
- equity Swap Involved: false
- id: F1
- transaction Shares: 62517
- transaction Price Per Share: 30.1062
- id: F3
- transaction Acquired Disposed Code: D
- shares Owned Following Transaction: 3513056
- direct Or Indirect Ownership: D
Purchases, sales, grants and option exercises are different transactions. The reported code identifies the action; it does not establish a motive.
Filing context
- Quantities and prices are shown in the units filed. No trade value is inferred from their product.
- Klee Justin B.: Co-Chief Executive Officer, Director.
- The filing reports a Rule 10b5-1 trading plan.
- F1: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on May 11, 2026.
- F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.72 to $29.71. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.72 to $30.29. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
Original sources
Prepared automatically from public filing data. Report a correction.